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HIGH ACTIVITY MUTANTS OF COCAINE 
ESTERASE FOR COCAINE HYDROLYSIS 
RELATED APPLICATIONS 
2 
manly recognized "stability-function trade-off' theory/hy­
pothesis, (14) protein residues that contribute to catalysis or 
ligand binding are not optimal for protein stability and, thus, 
there is a balance between the stability and function. Indeed, 
This application claims priority from U.S. Provisional 
Application Ser. No. 62/073,562 filed Oct. 31, 2014, the 
entire disclosure of which is incorporated herein by this 
reference. 
5 extensive studies (14, 17-22) demonstrate that thermostabi­
lizing mutations of enzymes decrease the catalytic activities 
of those enzymes and that mutations improving the catalytic 
activities decrease the thermal stability. Nevertheless, some 
CocE mutants with an improved thermal stability have 
10 successfully been designed and discovered in recently 
reported studies, (11, 23-26) and these thermostable mutants 
do not decrease, or only slightly decrease, the catalytic 
efficiency (kcalKM) of CocE against cocaine. Further animal 
GOVERNMENT SUPPORT CLAUSE 
This invention was made with Govermnent support under 
NIH number NIH ROI DA025100. The Government has 
certain rights in this invention. 
TECHNICAL FIELD 
15 behavior studies (27-29) reveal that these CocE mutants are 
promising in development of an enzyme therapy for cocaine 
abuse. 
Notably, one of the reported thermostable mutants of 
CocE, i.e. the Tl 72R/G 173Q mutant (known as drug RBP-The presently-disclosed subject matter relates to thera­
peutic enzymes, such as a mutant of bacterial cocaine 
hydrolase, in particular, cocaine esterase (CocE) polypeptide 
variant(s) with amino acid substitutions relative to wild type 
CocE. 
20 8000, with Clinica!Trials.gov Identifier of NCT01846481 in 
clinical development) designed through computational mod­
eling and simulations (11) has been advanced to the ran­
domized, double-blind, placebo controlled clinical trial 
phase II for cocaine overdose treatment. The Tl 72R/G 173Q 
INTRODUCTION 25 mutant ( denoted as enzyme El 72-173 here for convenience) 
was designed through introducing favorable noncovalent 
forces including a hydrogen bond between domains I and II 
of the protein. (11) This CocE mutant has an in vitro half-life 
of about 6 hours at 37° C. without decreasing the catalytic
Cocaine overdose and addiction have resulted in serious 
medical and social problems in modem society. (1) So far, 
there is no anticocaine medication approved by the Food and 
Drug Administration (FDA). (2, 3) Cocaine causes physi­
ological effects by binding with the dopamine transporter 
and, thus, blocking dopamine reuptake. The disastrous 
medical and social consequences of cocaine abuse have 
made the development of an anticocaine medication a high 
priority. However, despite decades of efforts, the classical 
pharmacodynamic approach has failed to yield a truly useful 
small-molecule receptor/transporter antagonist. The alterna­
tive pharmacokinetic approach is to interfere with the deliv­
ery of cocaine to its receptors and/or accelerate its metabo­
lism in the body. (2, 4-8) It would be an ideal to develop an 40 
exogenous enzyme which can accelerate cocaine metabo­
lism and produce biologically inactive metabolites. 
30 activity of CocE against cocaine. (11) The half-life of about 
6 hours at 37° C. is long enough for cocaine overdose
treatment, because one just needs to use the enzyme to 
rapidly detoxify cocaine. However, for cocaine addiction 
treatment, it is desirable to have a highly efficient cocaine-
35 metabolizing enzyme in the body with a residence time as 
long as possible. With a highly efficiently cocaine-metabo­
lizing enzyme in the body, whenever a cocaine abuser uses 
cocaine again, the enzyme would rapidly metabolize cocaine 
Bacterial cocaine esterase (CocE) has been recognized as 
the most efficient natural enzyme for hydrolyzing the natu­
rally occurring (-)-cocaine. (9) No other natural esterase has 45 
a catalytic activity for cocaine comparable to that of CocE. 
Studies have shown that CocE can help to prevent extreme 
cocaine toxicity and can even prevent the lethal effects of 
cocaine in some subjects. (10) However, a major obstacle to 
the clinical application of CocE is the thermoinstability of 50 
wild-type CocE with a half-life of only about 12 minutes at 
physiological temperature (37° C.). (11) It is highly desir­
able to develop thermostable mutants of CocE for therapeu-
tic treatment of cocaine abuse (overdose and addiction). In 
fact, thermal stability is a well-known common problem in 55 
protein drug development. (11) In general, the more ther­
mally stable a protein drug, the longer shelf half-life the 
protein drug can have. 
Generally speaking, the thermal stability of a protein can 
be improved by enhancing the weak interactions inside the 60 
enzyme through either noncovalent forces, such as hydrogen 
bonds, (12) or covalent linkage, such as disulfide bonds. (13) 
Particularly for an enzyme, besides improving its stability, it 
is also important to maintain the catalytic activity of the 
enzyme. However, it is much more challenging to engineer 65 
an enzyme with an improved stability without decreasing the 
catalytic activity. (14-16) In general, according to the com-
so that the cocaine abuser would not feel the stimulant 
effects of cocaine. 
To further develop an improved therapeutic enzyme for 
cocaine abuse treatment, one would like to both extend the 
half-life of E172-173 at 37° C. and improve the catalytic
efficiency against cocaine. It has been shown (11, 15, 26) 
that the thermal stability of El 72-173 at 37° C. can be
enhanced by extra mutations on E172-173. However, none 
of the reported extra mutations on El 72-173 improved the 
catalytic efficiency against cocaine. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This S=ary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. 
This Summary is merely exemplary of the numerous and 
varied embodiments. Mention of one or more representative 
features of a given embodiment is likewise exemplary. Such 
an embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 
excessive repetition, this Summary does not list or suggest 
all possible combinations of such features. 
US 9,879,240 B2 
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Here, a rationally-designed new mutant of El 72-173 is 
reported, which has not only considerably extended the in 
vitro half-life at 37° C., but also significantly improved the
catalytic efficiency against cocaine. The new CocE mutant 
(i.e. the Tl 72R/G 173Q/Ll 96C/1301 C mutant of CocE, 5 
denoted as enzyme E196-301 for convenience) was modi­
fied further via PEGylation in order to extend the in vivo 
residence time of the enzyme. The PEGylated E196-301 was 
used to fully protect mice from a lethal dose of cocaine (180 
mg/kg, LD100) for at least 3 days, indicating that it might be 10 
a more promising enzyme candidate for development of 
novel anticocaine therapeutics. 
Hence, the presently-disclosed subject matter includes a 
mutant of bacterial cocaine hydrolase. The presently-dis­
closed subject matter includes a new mutant of El 72-173. In 15 
some instances, the mutant enzyme has one or more cross­
subunit disulfide bond. In some embodiments, the one 
cross-subunit disulfide bond is a bond between C196a and 
C301b, or C301a and C196b. In some preferred embodi­
ments, the enzyme has a pair of cross-subunit disulfide 20 
bonds at C196a and C301b, and C301a and C196b. 
In some embodiments, the mutant of bacterial cocaine 
hydrolase provides improved stability and/or improved cata­
lytic activity against cocaine. In some embodiments, the 
mutant of bacterial cocaine hydrolase provides improved 25 
stability and/or improved catalytic activity against cocaine. 
In some embodiments, the mutant bacterial cocaine hydro­
lase includes at least one polyethylene glycol polymer chain 
attached thereto. In some embodiments, the pegylation 
improves stability of the enzyme. In some preferred embodi- 30 
ments, the hydrolase is conjugated to a maleimide linked 
polyethylene glycol. In some embodiments, the PEG mol­
ecule is branched. 
The presently disclosed subject matter further includes a 
pharmaceutical composition that includes a bacterial 35 
cocaine hydrolase variant and a suitable pharmaceutical 
earner. 
4 
tively), domain I is shown in red, domain II is shown in 
green, and domain III is shown in yellow. (FIG. lC) Key 
residues L196 (alb) and 1301 (alb) shown in ball and sticks 
on the dimer interface. 
FIGS. 2A-2C show plots of measured initial reaction rates 
(represented in µM min-1 per nM enzyme at 37° C., with
error bars) versus the substrate concentration for ( -)-cocaine 
hydrolysis catalyzed by CocE mutants: (FIG. 2A) Tl 72R/ 
G173Q (FIG. 28) T172R/G173Q/G4C/S10; (FIG. 2C) 
Tl 72R/G 173Q/Ll 96C/1301 C. 
FIG. 3 provides a plot of the remaining enzyme activity 
of the Tl 72R/Gl 73Q/L196C/I301C CocE against cocaine 
versus the time of the enzyme incubation at 37° C. The
catalytic activity of the incubated enzyme was assayed after 
0, 2, 9, 12, 31, and 100 days. 
FIGS. 4A-4D depict a crystal structure of the CocE 
mutant dimer. (FIG. 4A) Ribbons representation of the 
homodimeric molecule generated by applying 2-fold crys­
tallographic symmetry. The side chains of the cysteine 
residues forming intersubunit disulfide bonds are shown in 
a space filling representation. (FIG. 48) View of the dimer 
rotated 90° about a horizontal axis. (FIG. 4C) Fo-Fc electron
density (green, 3.5 sigma contour) calculated with the rig­
idly placed (before refinement) molecular replacement 
model having residues 196 and 301 altered to glycines. The 
final refined model in a stick representation is superimposed 
on the map. (FIG. 4D) Final SIGMAA-weighted 2Fo-Fc 
electron density map (blue, 1.0 sigma cutoff) in the region of 
the disulfide bond with the final model shown in a stick 
representation. 
FIG. 5 illustrates the in vivo effectiveness of E196-301 
(black squares) and the PEGylated E196-301 (red triangles) 
in the protection of mice from cocaine-induced lethality. A 
single dose (30 mg/kg) of E196-301 (PEGylated or unPE­
Gylated) was administered (i.v.) 1 min before the first i.p. 
administration of 180 mg/kg cocaine (n=5). The mice were 
challenged daily with 180 mg/kg cocaine until no mouse 
The presently-disclosed subject matter further includes a 
method of treating a cocaine-induced condition, which 
includes administering to an individual an effective amount 40 survived. E196-301 refers to the T172R/G173Q/L196C/
I301C mutant of CocE. of bacterial cocaine hydrolase variant or a pharmaceutical 
composition comprising a bacterial cocaine hydrolase vari­
ant, as described herein, to accelerate cocaine metabolism 
and produce biologically inactive metabolites. In some 
embodiments, the bacterial cocaine hydrolase variant exhib- 45 
its a one-hundred-fold or more increase in cocaine hydro­
lysis catalytic efficiency compared to compared to El 72-E73 
mutant hydrolase, which is currently in clinical trials for 
treatment of cocaine overdose. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The novel features of the subject matter of the present 
disclosure are set forth with particularity in the following 
description and in the appended sample claims. A better 
understanding of the features and advantages of the 
presently disclosed subject matter will be obtained by ref­
erence to the following detailed description that sets forth 
illustrative embodiments, in which the principles of the 
invention(s) are used, and the accompanying drawings. 
FIGS. lA-lC present a modeled E172-173 dimer struc­
ture. (FIG. lA) The time-dependent Ca-Ca distances 
between L196 and 1301 in the MD-simulated dimer struc­
ture of El 72-173. The letters a and b indicated after the 
FIG. 6 illustrates backbone superposition between the 
X-ray crystal structures of E172-173 and E196-301. E172-
173 is represented in green ribbons, and E196-301 is rep­
resented in red ribbons. The black arrow indicates the shift 
direction. Here, El 72-173 represents Tl 72R/G 173Q CocE, 
and El 96-301 refers to Tl 72R/G 173Q/Ll 96C/I301 C CocE. 
FIGS. 7A-7B show the time-dependence of important 
H . . .  0 distances (relevant to hydrogen bonds) from the 
50 MD-simulated El 72-173 and E196-301 structures. Y44HH-
CocO represents the distance between the hydroxyl hydro­
gen (denoted as HH) of the Y44 side chain and the carbonyl 
oxygen ( denoted as CocO) of (-)-cocaine benzoyl ester. 
Y118H-Coc0 refers to the distance between hydrogen (H) 
55 of the Yll 8 backbone and the carbonyl oxygen (CocO) of 
(-)-cocaine benzoyl ester. El 72-173 refers to Tl 72R/ 
G173Q CocE, and E196-301 refers to T172R/G173Q/ 
L196C/I301C CocE. 
FIG. 8 is an illustration of intermonomer disulfide bonds 
60 in the CocE mutant (E196-301) dimer refined in space group 
P65. The complete process of structure determination was 
carried out in a space group with lower symmetry than the 
true space group (P6522) in order to assess the effects of the 
residue numbers refer to subunits a and b, respectively. (FIG. 65 
18) The modeled El 72-173 dimer structure shown in rib­
bons (with a and b referring to subunits a and b, respec-
dimer being located on a crystallographic two-fold axis. 
Noncrystallographic symmetry restraints were not used dur­
ing refinement. The panels show the two, now not strictly 
identical, disulfide bonds for the final model (Rwork----0.17, 
US 9,879,240 B2 
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Rfree-0.21; yellow carbons) superimposed on the identical 
disulfide bonds in the model refined on the crystallographic 
two-fold axis (cyan carbons). 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: 1 is a nucleotide sequence encoding wild 
type cocaine esterase (CocE) polypeptide of SEQ ID NO: 2. 
SEQ ID NO: 2 is the amino acid of wild type CocE. 
SEQ ID NO: 3 is a nucleotide sequence encoding the 
CocE polypeptide variant of SEQ ID NO: 4; 
SEQ ID NO: 4 is an amino acid sequence encoding the 
CocE polypeptide variant having the following amino acid 
substitutions, as compared to wild type CocE: Tl 72R, 
Gl 73Q, L196C, and I301C. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently­
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem­
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
The presently-disclosed subject matter is illustrated by 
specific but non-limiting examples throughout this descrip­
tion. The examples may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
present invention(s). Each example is provided by way of 
explanation of the present disclosure and is not a limitation 
thereon. In fact, it will be apparent to those skilled in the art 
that various modifications and variations can be made to the 
teachings of the present disclosure without departing from 
the scope of the disclosure. For instance, features illustrated 
or described as part of one embodiment can be used with 
another embodiment to yield a still further embodiment. 
All references to singular characteristics or limitations of 
the present disclosure shall include the corresponding plural 
characteristic(s) or limitation(s) and vice versa, unless oth­
erwise specified or clearly implied to the contrary by the 
context in which the reference is made. 
All combinations of method or process steps as used 
herein can be performed in any order, unless otherwise 
specified or clearly implied to the contrary by the context in 
which the referenced combination is made. 
The presently-disclosed subject matter includes cocaine 
hydrolase (CocE) polypeptide variants. In some embodi­
ments, the CocE polypeptide variant is a mutant of El 72-
173. The CocE polypeptide variants disclosed herein each 
have enhanced catalytic efficiency for (-)-cocaine, as com­
pared to CocE mutants in the prior art, including CocE
mutant E 1 72-1 73.
The presently-disclosed subject matter further includes a 
pharmaceutical composition including a butyrylcholinest­
erase polypeptide variant, as described herein, and a suitable 
pharmaceutical carrier. The presently-disclosed subject mat­
ter further includes a method of treating a cocaine-induced 
condition comprising administering to an individual an 
6 
effective amount of a butyrylcholinesterase polypeptide 
variant, as disclosed herein, to lower blood cocaine concen­
tration. 
While the following terms used herein are believed to be 
well understood by one of ordinary skill in the art, defini­
tions are set forth to facilitate explanation of the presently­
disclosed subject matter. 
The terms "polypeptide", "protein", and "peptide", which 
are used interchangeably herein, refer to a polymer of the 
10 protein amino acids, or amino acid analogs, regardless of its 
size or function. Although "protein" is often used in refer­
ence to relatively large polypeptides, and "peptide" is often 
used in reference to small polypeptides, usage of these terms 
in the art overlaps and varies. The term "polypeptide" as 
15 used herein refers to peptides, polypeptides, and proteins, 
unless otherwise noted. The terms "protein", "polypeptide", 
and "peptide" are used interchangeably herein when refer­
ring to a gene product. Thus, exemplary polypeptides 
include gene products, naturally occurring proteins, 
20 homologs, orthologs, paralogs, fragments and other equiva­
lents, variants, and analogs of the foregoing. 
The term "variant" or "mutant" refers to an amino acid 
sequence that is different from the reference polypeptide by 
one or more amino acids, e.g., one or more amino acid 
25 substitutions. For example a CocE polypeptide variant dif­
fers from wild-type CocE by one or more amino acid 
substitutions, i.e., mutations. 
The terms "polypeptide fragment" or "fragment", when 
used in reference to a reference polypeptide, refers to a 
30 polypeptide in which amino acid residues are deleted as 
compared to the reference polypeptide itself, but where the 
remaining amino acid sequence is usually identical to the 
corresponding positions in the reference polypeptide. Such 
deletions can occur at the amino-terminus, carboxy-terminus 
35 of the reference polypeptide, or alternatively both. For 
example, CocE polypeptide fragment can have 1, 2, 3, 4, 5, 
6, 7, 8, 9, or 10 fewer amino acids than a full-length 
wild-type CocE polypeptide. CocE polypeptide fragments 
are also inclusive of fragments of CocE polypeptide vari-
40 ants. 
The term "cocaine" may refer to any and all forms of 
cocaine, including smoked, heated, inhaled, or injected 
cocaine. Further, in some embodiments, the term "cocaine" 
refers to any substance obtained, isolated and/or derived 
45 from the leaves of a coca plant. And in certain embodiments, 
the term "(-)-cocaine" refers to methyl (1R,2R,3S,5S)-3-
(benzoyloxy )-8-methy 1-8-azabicyclo [3 .2 .1 ]octane-2-car­
boxy late. 
Unless otherwise indicated, the term "administering" is 
50 inclusive of all means known to those of ordinary skill in the 
art for providing a preparation to a subject, including admin­
istration by inhalation, nasal administration, topical admin­
istration, intravaginal administration, ophthalmic adminis­
tration, intraaural administration, intracerebral 
55 administration, intravitreous administration, intracameral 
administration, posterior sub-Tenon administration, poste­
rior juxtascleral administration, subretinal administration, 
suprachoroidal administration, cell-based administration or 
production, rectal administration, and parenteral administra-
60 tion, including injectable such as intravenous administra­
tion, intra-arterial administration, intramuscular administra­
tion, and/or subcutaneous administration. Administration 
can be continuous or intermittent. A preparation can be 
administered therapeutically; that is, administered to treat an 
65 existing condition of interest. A preparation can be admin­
istered prophylactically; that is, administered for prevention 
of a condition of interest. 
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In some embodiments a subject will be administered an 
effective amount of at least one enzyme, compound and/or 
composition provided in the present disclosure. In this 
respect, the term "effective amount" refers to an amount that 
is sufficient to achieve the desired result or to have an effect 
8 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer­
ence to "an enzyme" includes a plurality of such enzymes, 
on an undesired condition. For example, a "therapeutically 
effective amount" refers to an amount that is sufficient to 
achieve the desired therapeutic result or to have an effect on 
undesired symptoms, but is generally insufficient to cause 
adverse side effects. The specific therapeutically effective 
dose level for any particular patient will depend upon a 
variety of factors including the disorder being treated and 
the severity of the disorder; the specific composition 
employed; the age, body weight, general health, sex and diet 
10 and so forth. 
of the patient; the time of administration; the route of 15 
administration; the rate of excretion of the specific com­
pound employed; the duration of the treatment; drugs used 
in combination or coincidental with the specific compound 
employed and like factors well known in the medical arts. 
For example, it is well within the skill of the art to start doses 20 
of a compound at levels lower than those required to achieve 
the desired therapeutic effect and to gradually increase the 
dosage until the desired effect is achieved. If desired, the 
effective daily dose can be divided into multiple doses for 
purposes of administration. Consequently, single dose com- 25 
positions can contain such amounts or submultiples thereof 
Unless otherwise indicated, all numbers expressing quan­
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently­
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia­
tions of in some embodiments ±50%, in some embodiments 
±40%, in some embodiments ±30%, in some embodiments 
±20%, in some embodiments ±10%, in some embodiments 
±5%, in some embodiments ±1 %, in some embodiments 
±0.5%, and in some embodiments ±0.1 % from the specified 
amount, as such variations are appropriate to perform the 
disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
to make up the daily dose. The dosage can be adjusted by the 
individual physician in the event of any contraindications. 
Dosage can vary, and can be administered in one or more 
dose administrations daily, for one or several days. Guidance 30 
can be found in the literature for appropriate dosages for 
given classes of pharmaceutical products. In further various 
aspects, a preparation can be administered in a "prophylac­
tically effective amount"; that is, an amount effective for 
prevention of a disease or condition. 35 For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between Additionally, the terms "subject" or "subject in need 
thereof' refer to a target of administration, which optionally 
displays symptoms related to a particular disease, pathologi-
cal condition, disorder, or the like. The subject of the herein 
disclosed methods can be a vertebrate, such as a mammal, a 40 
fish, a bird, a reptile, or an amphibian. Thus, the subject of 
the herein disclosed methods can be a human, non-human 
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea 
pig or rodent. The term does not denote a particular age or 
sex. Thus, adult and newborn subjects, as well as fetuses, 45 
whether male or female, are intended to be covered. A 
patient refers to a subject afflicted with a disease or disorder. 
The term "subject" includes human and veterinary subjects. 
In some embodiments the subject in need thereof will be 
suffering or will have been diagnosed cocaine addiction 50 
and/or related diseases, disorders, pathologies, or condi­
tions. 
As used herein, the terms "treatment" or "treating" relate 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
As will be recognized by one of ordinary skill in the art, 
the terms "reduce", "reducer", "reduction", "reducing", 
"suppression," "suppressing," "suppressor," "inhibition," 
"inhibiting" or "inhibitor" do not refer to a complete elimi­
nation of angiogenesis in all cases. Rather, the skilled artisan 
will understand that the term "reducing", "suppressing" or 
"inhibiting" refers to a reduction or decrease in a particular 
condition. Such reduction or decrease can be determined 
relative to a control. In some embodiments, the reduction or 
decrease relative to a control can be about a 1, 2, 3, 4, 5, 6, 
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 
24, 25,26,27,28, 29,30,31,32, 33,34,35,36, 37,38,39, 
40, 41,42,43,44, 45,46,47,48, 49, 50, 51, 52, 53, 54, 55, 
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, to any treatment of a condition of interest, including but not 
limited to prophylactic treatment and therapeutic treatment. 
As such, the terms treatment or treating include, but are not 
limited to: preventing a condition of interest or the devel­
opment of a condition of interest; inhibiting the progression 
55 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% 
decrease. 
of a condition of interest; arresting or preventing the devel­
opment of a condition of interest; reducing the severity of a 
condition of interest; ameliorating or relieving symptoms 
associated with a condition of interest; and causing a regres­
sion of the condition of interest or one or more of the 
symptoms associated with the condition of interest. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
As described herein, the presently-disclosed subject mat­
ter further includes pharmaceutical compositions compris­
ing at least one enzyme described herein together with a 
60 pharmaceutically acceptable carrier. 
The term "pharmaceutically acceptable carrier" refers to 
sterile aqueous or nonaqueous solutions, dispersions, sus­
pensions or emulsions, as well as sterile powders for recon­
stitution into sterile injectable solutions or dispersions just 
65 prior to use. Proper fluidity can be maintained, for example, 
by the use of coating materials such as lecithin, by the 
maintenance of the required particle size in the case of 
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dispersions and by the use of surfactants. These composi­
tions can also contain adjuvants such as preservatives, 
wetting agents, emulsifying agents and dispersing agents. 
Prevention of the action of microorganisms can be ensured 
10 
Preparations for oral administration can be suitably formu­
lated to give controlled release of the active compound. For 
buccal administration the compositions can take the form of 
tablets or lozenges formulated in conventional manner. 
The compositions can be formulated as eye drops. For 
example, the pharmaceutically acceptable carrier may com­
prise saline solution or other substances used to formulate 
eye drop, optionally with other agents. Thus, eye drop 
formulations permit for topical administration directly to the 
by the inclusion of various antibacterial and antifungal 
agents such as paraben, chlorobutanol, phenol, sorbic acid 
and the like. It can also be desirable to include isotonic 
agents such as sugars, sodium chloride and the like. Pro­
longed absorption of the injectable pharmaceutical form can 
be brought about by the inclusion of agents, such as alumi­
num monostearate and gelatin, which delay absorption. 
Injectable depot forms are made by forming microencapsule 
matrices of the drug in biodegradable polymers such as 
polylactide-polyglycolide, poly(orthoesters) and poly(anhy­
drides ). Depending upon the ratio of drug to polymer and the 
nature of the particular polymer employed, the rate of drug 
release can be controlled. Depot injectable formulations are 
also prepared by entrapping the drug in liposomes or micro­
emulsions which are compatible with body tissues. The 
injectable formulations can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorpo­
rating sterilizing agents in the form of sterile solid compo­
sitions which can be dissolved or dispersed in sterile water 
10 eye of a subject. 
The compositions can also be formulated as a preparation 
for implantation or injection. Thus, for example, the com­
pounds can be formulated with suitable polymeric or hydro­
phobic materials (e.g., as an emulsion in an acceptable oil) 
15 or ion exchange resins, or as sparingly soluble derivatives 
(e.g., as a sparingly soluble salt). The compounds can also 
be formulated in rectal compositions, creams or lotions, or 
transdermal patches. 
The presently-disclosed subject matter further includes a 
or other sterile injectable media just prior to use. Suitable 
inert carriers can include sugars such as lactose. 
20 kit that can include an enzyme and/or a pharmaceutical 
composition as described herein, packaged together with a 
device useful for administration of the compound or com­
position. As will be recognized by those or ordinary skill in 
the art, the appropriate administration-aiding device will 
25 depend on the formulation of the compound or composition 
that is selected and/or the desired administration site. For Suitable formulations include aqueous and non-aqueous 
sterile injection solutions that can contain antioxidants, 
buffers, bacteriostats, bactericidal antibiotics and solutes 
that render the formulation isotonic with the bodily fluids of 
the intended recipient; and aqueous and non-aqueous sterile 30 
suspensions, which can include suspending agents and 
thickening agents. 
The compositions can take such forms as suspensions, 
solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as suspending, stabilizing 35 
and/or dispersing agents. Alternatively, the active ingredient 
can be in powder form for constitution with a suitable 
vehicle, e.g., sterile pyrogen-free water, before use. 
The formulations can be presented in unit-dose or multi­
dose containers, for example sealed ampoules and vials, and 40 
can be stored in a frozen or freeze-dried (lyophilized) 
condition requiring only the addition of sterile liquid carrier 
immediately prior to use. 
example, if the formulation of the compound or composition 
is appropriate for injection in a subject, the device could be 
a syringe. For another example, if the desired administration 
site is cell culture media, the device could be a sterile 
pipette. 
The presently-disclosed subject matter includes mutants 
of bacterial cocaine hydrolase. The CocE polypeptide vari­
ants disclosed herein each have enhanced catalytic efficiency 
for ( -)-cocaine, as compared to CocE variant presently in 
trials. The presently-disclosed subject matter further 
includes a pharmaceutical composition including a bacterial 
cocaine hydro lase mutant, as described herein, and a suitable 
pharmaceutical carrier. The presently-disclosed subject mat­
ter further includes a method of treating a cocaine-induced 
condition comprising administering to an individual an 
effective amount of a bacterial cocaine hydrolase mutant, as 
disclosed herein, to accelerate cocaine metabolism and pro­
duce biologically inactive metabolites. 
In some embodiments, the present disclosure provides a 
CocE polypeptide variant for treatment of cocaine abuse. 
Moreover, the CocE polypeptide variant(s) of the present 
disclosure may have (i) an improved in vitro and/or in vivo 
half-life and/or (ii) an improved catalytic activity and/or 
catalytic efficiency, as compared to therapeutic enzymes 
previously known in the art. 
For oral administration, the compositions can take the 
form of, for example, tablets or capsules prepared by a 45 
conventional technique with pharmaceutically acceptable 
excipients such as binding agents ( e.g., pregelatinized maize 
starch, polyvinylpyrrolidone or hydroxypropyl methylcellu­
lose ); fillers ( e.g., lactose, microcrystalline cellulose or 
calcium hydrogen phosphate); lubricants (e.g., magnesium 50 
stearate, talc or silica); disintegrants ( e.g., potato starch or 
sodium starch glycolate); or wetting agents (e.g., sodium 
lauryl sulphate). The tablets can be coated by methods 
known in the art. 
Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid 
preparations can be prepared by conventional techniques 
with pharmaceutically acceptable additives such as suspend- 60 
ing agents ( e.g., sorbitol syrup, cellulose derivatives or 
hydrogenated edible fats); emulsifying agents (e.g. lecithin 
Some embodiments of the present disclosure provide a 
mutant of bacterial cocaine hydrolase. And in some embodi­
ments, the mutant of bacterial cocaine hydrolase provides 
55 improved stability and/or improved catalytic activity against 
or acacia); non-aqueous vehicles (e.g., almond oil, oily 
esters, ethyl alcohol or fractionated vegetable oils); and 
preservatives ( e.g., methyl or propyl-p-hydroxybenzoates or 65 
sorbic acid). The preparations can also contain buffer salts, 
flavoring, coloring and sweetening agents as appropriate. 
cocame. 
In certain embodiments, the CocE polypeptide variant of 
the present disclosure comprises a Tl 72R/G 173Q mutant. In 
some embodiments, the enzyme of the present disclosure 
comprises a T172R/G173Q/L196C/1301C mutant of 
cocaine esterase (CocE). In a particular embodiment, the 
CocE polypeptide variant of the present disclosure com­
prises El 72-173 enzyme. And in some embodiments, the 
CocE polypeptide variant(s) of the present disclosure com­
prises E196-301. Furthermore, in some embodiments, the 
enzyme(s) of the present disclosure may be modified by 
PEGylation. And in certain embodiments, treatment and/or 
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modification of an enzyme via PEGylation extends the in 
vivo residence time of the enzyme. 
Numerous derivatives of PEG and methods for making 
them and conjugating them to an enzyme are known in the 
12 
cross-subunit disulfide bonds that stabilize the dimer struc­
ture. The cross-subunit disulfide bonds were confirmed by 
X-ray diffraction. The designed L196C/1301C mutations
have not only considerably extended the in vitro half-life at
3 7° C. to > 100 days, but also significantly improved the
catalytic efficiency against cocaine by about 150%.
In addition, the thermostable E196-301 can be PEGylated 
to significantly prolong the residence time in a subject. For 
example, the PEGylated E196-301 can fully protect mice 
art and are suitable for use in the present invention. In some 
preferred embodiments, the PEG contains maleimide which 
reacts selectively with thiol residues in a Michael addition 
reaction. Other functionalized PEGs can be used in embodi­
ments, and adjusted according to desired properties of the 
PEGylated enzyme, for example in vivo residence time. 
In some embodiments, the enzyme( s) of the present 
disclosure may have an in vitro and/or in vivo half-life of 
between about 1 hour and about 1 year and/or of any amount 
10 from a lethal dose of cocaine (180 mg/kg, LDlOO) for at 
least 3 days, with an average protection time of about 94 
hours. This is the longest in vivo protection of mice from the 
lethal dose of cocaine demonstrated within all studies using 
of time within that range. 
Additionally, in certain embodiments, the enzyme(s) of 15 
the present disclosure may have an in vitro and/or in vivo 
half-life of between about 4 and about 8 hours, between 
about 5 and about 7 hours or between about 5.5 and about 
6.5 hours. And in some embodiments, the enzyme(s) of the 
present disclosure have an in vitro and/or in vivo half-life of 20 
about 6 hours. Moreover, any such half-life is or can be 
maintained at physiological temperature in a human subject. 
In other words, in certain embodiments, the enzyme(s) of the 
present disclosure may have an in vitro and/or in vivo 
half-life of between about 4 and about 8 hours at a tern- 25 
perature at or around physiological temperature in a human 
subject. Thus, in some embodiments, the enzyme(s) of the 
present disclosure have an in vitro and/or in vivo half-life of 
between about 4 and about 8 hours between about 36.5° C.
and about 37.5° C., which is normal human body tempera- 30
ture. 
an exogenous enzyme reported so far. Hence, El 96-301 may 
become a valuable therapeutic enzyme for cocaine abuse 
treatment, and it demonstrates that a general design strategy 
and protocol to simultaneously improve both the stability 
and function are feasible for rational protein drug design. 
Accordingly, in some embodiments, an enzyme of the 
present disclosure may be pegylated. In other words, in 
some embodiments, at least one chain of polyethylene 
glycol (PEG) polymer may be attached to the enzyme of 
interest. And in certain embodiments, the pegylation (pro­
cess via which the enzyme is pegylated) of an enzyme may 
improve the enzyme's residence time in a subject. 
Further, in some embodiments, the present disclosure is 
directed to a method of protecting a subject from an over­
dose and/or a lethal dose of cocaine. The method includes at 
least the step of administering an amount of at least one 
enzyme of the present disclosure to a subject. In some 
embodiments, administration of an effective amount of an 
enzyme of the present disclosure can protect a subject from 
and overdose and/or a lethal dose of cocaine for between 
about 24 and about 100 hours. In certain embodiments, 
Meanwhile, in other embodiments, the enzyme(s) of the 
present disclosure may have an in vitro and/or in vivo 
half-life of greater than about 100 days. And in some 
embodiments, the enzyme(s) of the present disclosure have 
an in vitro and/or in vivo half-life of between about 1 and 
about 150 days. Moreover, any such half-life is or can be 
maintained at physiological temperature in a human subject. 
35 administration of an effective amount of an enzyme of the 
present disclosure protects a subject from overdose and/or 
lethal dose of cocaine for at least about 48 hours, at least 
about 72 hours, and/or at least about 96 hours. 
In other words, in certain embodiments, the enzyme(s) of the 
present disclosure may have a half-life of greater than about 
100 days at a temperature at or around physiological tem­
perature in a human subject. Thus, in some embodiments, 
the enzyme(s) of the present disclosure have an in vitro 
and/or in vivo half-life of greater than or equal to about 100 
days at about 36.5° C. and about 37.5° C. and/or at a normal
and/or an average human body temperature. 
In certain embodiments, the present disclosure further 
provides a method of treating, preventing and/or reducing 
substance abuse, such as cocaine abuse and/or cocaine 
addiction. In the present disclosure, "substance abuse" may 
include, for example, craving, drug seeking, and/or self­
administration. The method comprises at least the step of 
administering a CocE polypeptide variant provided in the 
present disclosure to a subject. In some embodiments, the 
subject is in need of treatment. 
In some embodiments, the enzyme of the present disclo-
40 sure comprises a dimer. And in certain embodiments, the 
enzyme of the present disclosure has been modified to 
include disulfide bonds between the two subunits of the 
dimer. Indeed, in certain embodiments, disulfide bonds are 
introduced between the subunits of an enzyme of the present 
45 disclosure. These disulfide bonds are referred to as cross­
subunit disulfide bonds. 
Additionally, in some embodiments, the enzyme of the 
present disclosure includes at least one mutation that 
increases the size of the active site cavity of the enzyme. And 
50 in certain embodiments, the at least one mutation improves 
the catalytic activity of the enzyme. 
The presently-disclosed subject matter is illustrated by the 
following specific but non-limiting examples. The following 
examples may include compilations of data that are repre-
55 sentative of data gathered at various times during the course 
of development and experimentation related to the present Cocaine esterase is known as the most efficient natural 
enzyme for cocaine hydrolysis. A major obstacle to the 
clinical application of wild-type CocE is the thermoinsta­
bility with a half-life of only about 12 minutes at 37° C. The
previously designed Tl 72R/G 173Q mutant ( denoted as 60 
enzyme E172-173) with an improved in vitro half-life of 
about 6 hours at about 37° C. is currently in clinical trial
Phase II for cocaine overdose treatment. 
invention. 
EXAMPLES 
Mutant Design: Insights from Molecular Modeling. 
The inventors of the present disclosure first aimed to 
stabilize the dimer structure of El 72-173 and then analyzed 
the possibly stabilized dimer structure and estimated how 
the activity of the dimer would change. The computational 
design strategy relied on the molecular dynamics (MD)­
simulated dimer structure of El 72-173 and the idea that the 
Through molecular modeling and dynamics simulation, 
the inventors of the present disclosure have designed and 65 
characterized a new mutant of El 72-173 with extra L196C/ 
1301C mutations (denoted as enzyme E196-301) to produce 
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dimer structure can be stabilized by introducing disulfide 
bonds between the two subunits of the dimer. So, the 
inventors carried out a sufficiently long MD simulation (50 
ns) on the E172-173 dimer structure in order to obtain a 
dynamically stable dimer structure. To search for appropri­
ate mutational sites to introduce the cross-subunit disulfide 
bonds, a self-developed script was used to scan the key 
internuclear distances between the Ca atoms of the residues 
14 
lar modeling and X-ray structural analysis (see below) of the 
dimer structure of the Tl 72R/G 173Q/1, 196C/1301 C mutant 
also suggested that the extra L196C/1301C mutations could 
slightly increase the size of the active site cavity of the 
enzyme and, thus, might improve the catalytic activity. 
In Vitro Characterization of the Designed Tl 72R/G 173Q/ 
L196C/1301 C Mutant. 
on the dimer interface from the collected snapshots of the 
MD trajectory. Essentially, each pair of residues from dif­
ferent subunits was evaluated computationally for the simu­
lated Ca-Ca distance. If the simulated Ca-Ca distance was 
within 7 A, the pair of the residues would be checked 
manually for further evaluation of the detailed interactions. 
The most hopeful pair of residues may be mutated to 
cysteine for introducing possible cross-subunit disulfide 
bond(s). 
Based on the computational insights, the inventors carried 
out wet experimental tests, including site-directed mutagen-
lO esis, protein expression, purification, and enzyme activity 
assays on the Tl 72R/Gl 73Q and Tl 72R/Gl 73Q/1,196C/ 
1301C mutants of CocE. For comparison, the inventors of 
the present disclosure also prepared and characterized the 
15 Tl 72R/G 1730/G4C/Sl OC mutant which has been known to 
Based on the analysis of the MD trajectory, L196C/1301C 
mutations satisfied all of the structural requirements. Sum­
marized in Table 1 are the maximum, minimum, and average 20 
values of the Ca-Ca distances associated with the stable 
MD trajectory (10 to SO ns) in comparison with the corre­
sponding Ca-Ca distances in the X-ray crystal structure. As 
seen in Table 1, the detailed analysis of the MD trajectory 
predicted that extra L196C/1301C mutations on E172-173 25 
may introduce the desirable cross-subunit disulfide bonds 
between the two subunits of the El 72-173 dimer. Depicted 
in FIG. lA are the simulated time-dependent Ca-Ca dis­
tances for the pair of residues. Depicted in FIG. 18 is the 
MD-simulated El 72-173 dimer structure consisting of sub- 30 
units a and b. FIG. lC is the detailed information about the
have a pair of cross-subunit disulfide bonds. (26) All of the 
mutants were expressed similarly well. To minimize the 
possible systematic experimental errors of the kinetic data, 
all of the three mutants were simultaneously prepared and 
characterized under the same experimental conditions, 
which allowed for fair comparison of their catalytic activity 
against (-)-cocaine. Michaelis-Menten kinetics of the enzy­
matic hydrolysis of (-)-cocaine was determined by perform­
ing the sensitive radiometric assays using [3H](-)-cocaine 
(labeled on its benzene ring) with varying concentrations of 
the substrate. Depicted in FIG. 2 are the measured kinetic 
data, and summarized in Table 2 are the kinetic parameters 
determined at 37° C. 
As seen in Table 2, kcat=2600 min-1, KM=2.9 µM, and 
kcat/KM=9.2xl 08 min-1 M-1 for the Tl 72R/G 173Q mutant 
under the current clinical development. Compared to the 
Tl 72R/G 173Q mutant, the Tl 72R/G 173Q/G4C/S 1 OC 
mutant has a slightly smaller kcat value (2340 min-1) and a 
slightly smaller KM value (2.1 µM). Overall, the catalytic 
MD-simulated El 72-173 dimer structure concerning this
important pair of residues. The interface between the two
subunits is mainly composed of some residues from all of
the three domains (I, II, and III) in the form of a-helices,
�-sheets, and loops. L196 is located on one a-helix (E184-
Nl 97) in domain II, 1301 is located on a loop in domain 1.
TABLE 1 
35 efficiency (kcat/KM) changed about 20% (from 9.2x108 
min-1 M-1 to 1.lx109 min-1 M-1). Interestingly, the new 
mutant (Tl 72R/G 173Q/Ll 96C/I301 C) designed in the pres­
ent study has both a significantly increased kcat value (3450 
min-1) and a significantly smaller KM value (1.5 µM). As a 
Maximwn, Minimum, and Average Ca-Ca Distances between Key 
Residues in the El 72-173 Dimer Obtained from the 50 ns MD 
Simulation in Comparison with the Corresponding Ca-Ca 
Distances in the X-ray Crystal Structure 
40 result, the catalytic efficiency (kcat/KM=2.3x109 min-1 
M-1) of the T172R/G173Q/L196C/I301C mutant has a,
-150% improvement from that (kcat/KM=9.2x108 min-1
M-1) of the Tl 72R/Gl 73Q mutant under the current clinical
development.
Ca-Ca distances (A) 45 
El 72-173 structure L196a-1301b 1301a-L196b 
Crystal structure of El 72-173a 7.29 7.20 
MD-simulated El 72-173 Maximum 10.85 7.19 
structure (50 ns MDl Minimum 5.16 4.51 
Average 7.15 5.44 
aT172RIG173Q CocE (E172-173) crystal structure (PDB ID: 3!2F). 
hpully relaxed MD simulation of the El 72-173 dimer structure starting from the crystal 
structure. 
50 
55 According to the locations of these residues, it is highly 
possible to introduce a pair of cross-subunit disulfide bonds 
(C196a-C301 b and C301a-C196b) through the L196C/ 
1301C mutations on E172-173. The computationally 
designed new mutant, i.e. the Tl 72R/G 173Q/Ll 96C/1301 C 
mutant (denoted as enzyme E196-301 for convenience), 60 
may have a pair of cross-subunit disulfide bonds: one 
between C196 of subunit a (C196a) and C301 of subunit b 
(C301 b ), and the other between C301 of subunit a (C301a) 
and C196 of subunit b (C196b). 
It is also interesting to note that residue 1301 is on a loop, 65 
implying that the loop flexibility may help to form the 
desirable cross-subunit disulfide bonds. In addition, molecu-
TABLE 2 
Kinetic Parameters Determined for (-)-Cocaine Hydrolysis 
Catalyzed by the Tl 721t/Gl 73Q, Tl 72R/Gl 73Q/G4C/S10C, 
and Tl 72R/G 1730/L196C/1301 C Mutants of CocEa 
kca/KM 
CocE mutant kca, (min-
1) KM (µM) (min-
1 M-1) 
T172R/G173Q 2600 2.9 9.2 x 108 
Tl 72R/Gl 73Q/G4C/S10C 2340 2.1 1.1 x 109 
Tl 72R/Gl 73Q/L196C/1301C 3450 1.5 2.3 x 109 
Based on the encouraging kinetic data, the purified pro­
tein of the Tl 72R/G 173Q/Ll 96C/I301 C mutant was tested 
for the thermal stability at 37° C. For this purpose, the 
enzyme was incubated at 37° C., and the catalytic activity of 
the incubated enzyme against cocaine was assayed at dif­
ferent time points. 
As seen in FIG. 3, the enzyme showed a relatively faster 
decrease of the activity ( around 20%) during the first a few 
days, compared to the last 90 days. The relatively faster 
decrease of the activity during the first a few days is likely 
due to the possibility that certain percentage of the mutant 
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protein molecules had not yet formed the expected cross­
subunit disulfide bonds before the thermal stability test. 
Although the cross-subunit disulfide bonds were expected to 
form spontaneously (as no extra oxidation reagent was 
employed in this study to facilitate the disulfide bond 5 
formation), a small percentage of the new mutant (Tl 72R/ 
G173Q/L196C/I301C) molecules did not really form the 
cross-subunit disulfide bonds. Those Tl 72R/ 
Gl 73Q1L196C/I301C mutant molecules without the cross­
subunit disulfide bonds could lose the activity more rapidly, 10 
like the Tl 72R/G 173Q mutant which has an in vitro half-life 
of - 6  h at 37° C. (11) However, after the first few days, the 
enzyme activity decreased very slowly. Within the last 90 
days, the enzyme activity decreased for only, -15%. Overall, 
the enzyme still retained more than 60% of the enzyme 15 
activity after incubation at 37° C. for 100 days, indicating 
that the in vitro half-life of the Tl 72R/Gl 73Q/L196C/I301C 
mutant at 37° C. should be longer than 100 days. 
Confirmation of the Cross-Subunit Disulfide Bonds. 
16 
cess. A slightly larger active site could better accommodate 
such a large substrate like cocaine and, thus, make the 
enzyme more active against cocaine; the similar type of 
structure-activity correlation was noted for previously 
designed mutants of human butyrylcholinesterase (BChE). 
(31) The BChE mutants with a slightly larger active site
have a significantly improved catalytic efficiency against
cocaine without changing substrate specificity. (31, 32)
To further understand why E196-301 has an improved 
catalytic activity against cocaine compared to El 72-173, the 
present inventors performed MD simulations on the transi­
tion state (TS 1) for the initial reaction step of (-)-cocaine 
hydrolysis catalyzed by El 72-173 and E196-301. Previous 
computational studies 33 on the catalytic reaction mecha-
nism for wild-type CocE-catalyzed hydrolysis of (-)-co­
caine revealed that the CocE-catalyzed cocaine hydrolysis is 
initialized by the nucleophilic attack on the carbonyl carbon 
of (-)-cocaine benzoyl ester by the hydroxyl oxygen of 
Serl! 7, and that the transition state is stabilized by hydrogen 
With the encouraging data about the significant improve­
ment in both the catalytic activity and thermal stability at 3 7° 
C., the inventors of the present disclosure have determined 
the crystal structure of the T172R/G173Q/L196C/I301C 
mutant in order to directly confirm the formation of the 
cross-subunit disulfide bonds between L196C and I301C. 
20 bonding of the carbonyl oxygen of cocaine benzoyl ester 
with the hydroxyl group ofY 44 side chain and the NH group 
of the Yll 8 backbone. (33) The (-)-cocaine hydrolysis 
catalyzed by El 72-173 or El 96-301 is expected to follow 
the same catalytic reaction mechanism, as the residues #196 
25 and #301 are all far away from the active site. Based on the 
established mechanistic understanding, the stronger the 
hydrogen bonding of the carbonyl oxygen of the substrate 
with Y 44 side chain and Yl 1 8  backbone, the more active the 
The CocE mutant crystallized with one monomer in the 
asymmetric unit, but a symmetry related molecule forms an 
extensive interface, burying over 1900 A of solvent-acces­
sible surface area as calculated by the PISA server. (30) The 
dimer formed by these two molecules (FIGS. 4A and B) 30 
corresponds to previously reported structures of unlinked 
(PDB 3PUH) and covalently linked (PDB 3PUI) CocE 
dimers. (2 6) Thus, the expected homodimer was formed in 
the crystals. Initial difference maps using the rigidly placed 
(without refinement) CocE mutant structure with glycine 35 
residues substituted at residue positions 196 and 301 showed 
strong positive Fo-Fc difference electron density for the 
cysteine side chains at the dimer interface (FIG. 4C) con­
sistent with disulfide bond formation. Subsequent refine­
ment of the model with cysteine residues introduced at these 40 
positions and no disulfide restraints gave well-defined 
weighted 2Fo-Fc density and excellent geometry consistent 
with disulfide bond formation across the subunits (FIG. 4D, 
see FIGS. 4A and B). The sulfur-to-sulfur distance is 2.0 A 
and the dihedral angle is 94 °. 
enzyme. 
The general strategy and protocol for performing MD 
simulation on a transition state of enzymatic reaction using 
the classical force field have been described in detail else­
where. (34, 35) Based on the protoco 1,34 the lengths of the 
transition bonds (i.e., the covalent bonds that gradually form 
or break during the reaction step associated with the tran­
sition state) in the transition state are restrained according to 
the previous QM/MM reaction-coordinate calculations, 
assuming that the these bond lengths do not significantly 
change after the mutations. The transition-state modeling in 
the present study was based on the inventors' QM/MM­
optimized TS! structure33 for CocE-catalyzed hydrolysis of 
(-)-cocaine. It is reasonable to assume that the transition 
bond lengths in the TS! structure will not significantly 
change after the Tl 72R/G 173Q or Tl 72R/G 1730JL196C/ 
45 1301C mutations. So, MD simulations were carried out on 
the TS! structures corresponding to E172-173 and E196-
301, with the transition bond lengths restrained. 
In summary, the crystal structure of the enzyme unam­
biguously confirms the presence of the engineered intersub­
unit disulfide bonds. Since the dimer axis corresponds to a 
crystallographic 2-fold axis (space group P 6522), the struc­
ture was also refined in a lower symmetry group (P 65), 50 
which places a disulfide-linked dimer in the asymmetric unit 
and does not therefore impose symmetry on the model. This 
refinement resulted in geometry for the two disulfide bonds 
that is nearly identical to that present in the dimer on the 
crystallographic 2-fold axis (FIG. 8), eliminating the possi- 55 
bility of any artifact from this placement. 
Structure-Activity Correlation. 
Superposition between the X-ray crystal structures of 
El 72-173 (representing the Tl 72R/G 173Q mutant) and 
E196-301 (representing the T172R/G173WL196C/1301C 60 
mutant) revealed a root-mean-square deviation (RMSD) 
value of 0.299 A, indicating the high similarity of the two 
protein structures. However, the superposition also revealed 
a slight shift of two a-helices (H2 and H3 in domain II) in 
E196-301 compared to that in EI72-173 (see FIG. 6). The 65 
shift created a slightly enlarged active-site cavity in E196-
301, which could possibly favor the catalytic reaction pro-
Depicted in FIG. 7 are the simulated time-dependent 
H . . .  0 distances (relevant to the hydrogen bonds) in 
El 72-173 and El 96-301 during the MD simulations for 50 
ns. The detailed analysis of the key H . . . 0 distances 
between enzyme residues and cocaine is summarized in 
Table 3. In El 72-173, the H ... 0 distance between CocO 
and Y44HH was 3.02 A in maximum, 1.44 A in minimum, 
and 1.87 A in average, while the H ... 0 distance between 
CocO and Y114H was 3.14 A in maximum, 1.61 A in 
minimum, and 2.1 6  A in average. In E196-301, the H ... 0 
distance between Y44HH and CocO was 3.17 A in maxi­
mum, 1.44 A in minimum, and 1.80 A in average, while the 
H ... 0 distance between CocO and Y114H was 2.89 A in 
maximum, 1.61 A in minimum, and 2.13 A in average. 
According to these simulated H ... 0 distances, the H ... 
O distances of the two hydrogen bonds in E196-301 are all 
shorter than the corresponding ones in El 72-173, suggesting 
that cocaine has the stronger hydrogen bonding with E196-
301 compared to that with E172-173 in the TS! structure. 
The enhanced hydrogen bonding helps to stabilize the 
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transition state (TS 1) structure during the catalytic reaction 
process and, thus, lower the energy barrier, which explains 
the improved catalytic activity of the new mutant. 
In Vivo Protection of Mice Against Cocaine-Induced 
Lethality. 
For development of an effective cocaine abuse treatment 
using a cocaine-metabolizing enzyme, it is highly desired to 
have a long residence time of the enzyme in the body. To 
have a long residence time in the body, the enzyme must be 
thermostable at 37° C. for a sufficiently long time. So, it is 10 
a necessary condition, but not a sufficient condition, for an 
enzyme having a long residence time in the body to have a 
long in vitro half-life of the enzyme at 37° C. An enzyme 
may be eliminated rapidly from the body, even if it is very 
thermostable at 37° C. In this consideration, PEGylation is 15 
a popularly used strategy to prevent the possible rapid 
elimination of a protein from the body. Hence, the inventors 
further engineered E196-301 through the PEGylation modi­
fication. Activity assays confirmed that the PEGylated E196-
301 completely maintained its activity against cocaine as 20 
that of El 96-301. 
TABLE 3 
18 
in vivo protection of mice from a lethal dose of cocaine (180 
mg/kg, LI3100) demonstrated so far within all in vivo 
studies using an exogenous enzyme. 
It should be pointed out that the in vivo studies described 
above are a simplified animal model (using a high dose of 
enzyme and high doses of cocaine for convenience of animal 
behavior observation) to show the long residence time of the 
PEGylated El 96-301. As discussed earlier in this report, the 
long residence time of the enzyme is crucial for an effective 
enzyme-based cocaine addiction treatment. For practical 
cocaine addiction treatment using a cocaine-metabolizing 
enzyme in humans, the cocaine doses are much lower (a 
typical cocaine addiction dose is -1 mg/kg, which is much 
lower than the lethal dose of 180 mg/kg used in the animal 
model) and, correspondingly, the required dose of the 
enzyme for effective cocaine metabolism may be less than 
about 30 mg/kg. 
Concluding Remarks. 
Molecular dynamics simulation and subsequent structural 
analysis on the dimer structure of a therapeutic cocaine­
metabolizing enzyme, i.e. El 72-173 (which is the Tl 72R/ 
G 173Q mutant of CocE), led to the prediction that the extra 
L196C/1301 C mutations on El 72-173 can produce cross­
subunit disulfide bonds in the dimer. The formation of 
Summary of the MD-Simulated Key Distances (in A) between 
the Hydrogen Atoms of Key Residue and the Carbonyl 
Oxygen of (-)-Cocaine Benzoyl Ester in the 
Rate-Determining Transition-State Structures of CocE 
25 cross-subunit disulfide bonds were expected to stabilize the 
dimer structure and also improve the catalytic activity 
against cocaine. 
Distances (A) 
Hydrogen bond Maximum Minimum 
Y44HH-Coc0b E172-173a 3.02 1.44 
E196-301 a 3.17 1.44 
Y118H-Cococ E172-173a 3.14 1.61 
E196-301 a 2.89 1.61 
Average 
1.87 
1.80 
2.16 
2.13 
30 
Following the computational prediction, in vitro experi­
mental studies have demonstrated that the computationally 
designed new CocE mutant (Tl 72R/G 173Q/Ll 96C/1301C), 
i.e. E196-301, indeed has a significantly improved catalytic
efficiency against cocaine and a considerably extended in 
vitro half-life (>100 days) at 37° C. 
The predicted cross-subunit disulfide bonds in the E196-
35 301 dimer structure were confirmed by X-ray diffraction. In 
aE172-173 represents T172RIG173Q CocE, and E196-301 refers to T172RIG173Q/ 
L196C/!301 C CocE. 
by44HH-Coc0 represents the distance between the hydroxyl hydrogen (denoted as HH) 
of the Y44 side chain and the carbonyl oxygen (denoted as CocO) of(-)-cocaine benzoyl 
ester. 
addition, in vivo studies in mice demonstrated that the 
PEGylated E196-301 can fully protect mice from a lethal 
dose of cocaine (180 mg/kg, LD 100) for at least 3 days, with 
the average protection time being about 94 hours. All of the 'Yl 18H-Coc0 refers to the distance between the hydrogen (H) of the Yl 18 backbone and 
the carbonyl oxygen (CocO) of (-)-cocaine benzoyl ester. 
To test the ability of E196-301 (unPEGylated, unless 
specified otherwise) and the PEGylated E196-301 in pro­
tecting mice (n= 5) from a lethal dose of cocaine, E196-301 
or the PEGylated E16-301 was administered intravenously 
(at a single dose of 30 mg/kg) 1 min before the first 
intraperitoneal administration of 180 mg/kg cocaine 
(LDlOO). 
40 data suggests that the currently designed enzyme E196-301 
with improved thermal stability and catalytic activity against 
cocaine is more valuable than the existing therapeutic 
enzyme El 72-173, which is under clinical trial phase II for 
cocaine overdose treatment. The encouraging outcomes of 
Depicted in FIG. 5 are the data for the in vivo protection 
45 this study also suggest that the structure-and-mechanism­
based computational design and integrated computational­
experimental approach are promising for rational protein 
drug design. The general computational protein design strat­
egy and approach to simultaneously improve both the pro-of mice provided by E196-301 and the PEGylated E196-301 
against the cocaine-induced lethality. As seen in FIG. 5, 
E196-301 protected the mice from death after the first 
injection of 180 mg/kg cocaine but lost the efficacy at the 
second injection of 180 mg/kg cocaine 24 hours later. The 
PEGylated E196-301 was able to fully protect the mice 
(n= 5) for at least 72 hours from the acute toxicity of a lethal 55 
dose of cocaine (180 mg/kg, LDlOO): no mouse died after 
the fourth cocaine challenge at 72 hours, three mice died 
after the fifth cocaine challenge at 96 hours, and the remain­
ing two mice died after the final (sixth) cocaine challenge at 
120 hours (see FIG. 5). According to the data depicted in 60 
FIG. 5, the PEGylated E196-301 can protect the three mice 
(60%) with the protection time (tp) being between 72 and 96 
h: 72 h<tp<96 h, or tp=84± 12 h. For the remaining two mice 
( 40%), 96 h<tp<120 h, or tp=108±12 h according to the data 
50 tein stability and function may also be valuable for engi­
neering other proteins. Intermonomer disulfide bonds in the 
CocE mutant (E196-301) dimer refined in space group P65 
is shown in FIG. 8. 
Material and Methods 
Computational Methods Used for the Mutant Design. 
For the molecular dynamics (MD) simulations on the 
in FIG. 5. Overall, the PEGylated E196-301 can protect the 65 
mice with an average protection time ( denoted as <tp> for 
convenience) of -94 h, i.e. <tp>=-94 h. This is the longest 
CocE dimer structures, the starting structure of the El 72-
173 dimer was the X-ray crystal structure ( deposited in the 
Protein Data Bank) at 2.0 A resolution (PDB ID: 3I2F) (26) 
and the starting structure of the E196-301 dimer was the 
X-ray crystal structure determined in the present study. In
order to simulate the TSl structures for the enzymatic
hydrolysis of cocaine, the transition bond lengths in the TSl
structure were restrained as those in previously QM/MM­
optimized TSl structure33 for CocE-catalyzed hydrolysis of
(-)-cocaine. A transition bond in the TSl structure refers to
a covalent bond which gradually forms or breaks in the
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transition state (TS!) during the first step of the chemical 
reaction process. According to previously reported QM/MM 
reaction-coordinate calculations33 on CocE-catalyzed 
hydrolysis of (-)-cocaine, there are three transition bonds in 
the TS! structure: (1) the internuclear distance (1.93 A) 5 
between the carbonyl carbon of (-)-cocaine benzoyl ester 
and the hydroxyl oxygen (Oy) of Serl 17 side chain; (2) the 
internuclear distance (1.38 A) between the hydroxyl oxygen 
(Oy) and hydroxyl hydrogen (Hy) of Serll 7 side chain; 
(3) the internuclear distance (1.19 A) between the hydroxyl 10 
hydrogen (Hy) of Serll 7 side chain and the nitrogen (NE) 
atom of His287 side chain. These three transition bond 
lengths were used in all of the MD simulations on the TS! 
structures. All of the mutations (Tl 72R/Gl 73Q and L196C/ 
1301C) examined in the present study were made on the 15 
amino acid residues (#172, #173, #196, and #301) that are 
far away from the active site. So, these mutations are not 
expected to dramatically change the catalytic mechanism or 
significantly affect the transition bond lengths. The similar 
approximation was used in previously reported computa- 20 
tional modeling studies (34, 36) on other esterases, leading 
to successful design and discovery of new mutants with a 
significantly improved catalytic activity. 
The general procedure for carrying out the MD simula­
tions in the present study was similar to that used in 25 
pr�viously-reported computational studies (34, 37-39) 
Bnefly, all molecular mechanics-based energy minimization
and MD simulations were carried out by using the AMBER 
9 program package. The Amber force field (ffD3) was used 
to esta�lish the potentials of protein 40 For each system, 30 
countenons (Na) were used to neutralize the system and, 
then, the neutralized system was immersed in an orthorhom­
bic box of TIP3P water molecules 41 with a minimum 
solute-wall distance of 10 A. The whole system was care-
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to 300 K over 60 ps. Then, a 50 ns MD simulation was 
per-t:ormed under the normally adopted temperature (300 K). 
Dunng the MD simulation, the Particle Mesh Ewald (PME) 
method was employed to deal with the long-range electro­
static i�teractions. 42 The SHAKE procedure was applied to 
40 
constram the lengths of all covalent bonds involving hydro­
gen atoms, 43 with a time step of 2.0 fs. The atomic 
coordinates were saved every 1 ps for subsequent sampling 
20 
resin (Thermo Fisher Scientific). The eluted fractions were 
concentrated by using an Amicon Ultra-SOK centrifuge 
(Millipore, Billerica, Mass.). The enzyme concentrations 
were determined using a CB-Protein Assay kit (from CAL­
BIOCHEM) with bovine serum albumin as a standard. 
Enzyme Activity Assays. 
To measure (-)-cocaine and benzoic acid, the product of 
(-)-cocaine hydrolysis catalyzed by BChE, sensitive radio­
metric assays were used based on toluene extraction of 
(3�](-)-cocaine labeled on its benzene ring. (45) In brief, to 
1mtrnte the enzymatic reaction, 100 nCi of [3H](-)-cocaine 
was mixed with the solution of the purified enzyme. The 
enzym�tic reactions pr�ceeded at 37
° C. with varying con­
cen�rat10ns of ( -)-cocame. The reactions were stopped by 
addmg 200 µL of 0.1 M HCI, which neutralized the liberated 
benzoic acid whereas ensuring a positive charge on the 
residual (-)-cocaine. [3H]Benzoic acid was extracted by 1 
�L of toluene and measured by scintillation counting. 
Fm�lly, t�e measured (-)-cocaine concentration-dependent 
rad10metnc data were analyzed by using the standard 
Michaelis-Menten kinetics with Prism 5 (GraphPad Soft­
ware Inc., San Diego, Calif.). 
To determine the in vitro half-life of the enzyme at 37° C., 
the enzyme was diluted to 200 µg/mL, stored in sealed glass 
tubes and incubated at 37° C. The tubes were sealed to avoid 
the possible vaporization-associated change in the volume. 
One tube will be taken out of the incubation cabinet at 
various time points (0, 2, 9, 12, 31, and 100 days) and 
assayed for the catalytic activity against ( -)-cocaine as 
mentioned above. The percentage of remaining activity was 
plotted against the incubation time. 
Crystallization and Structure Determination. 
Cryst�ls of the designed new mutant of CocE were grown 
by hangmg drop vapor diffusion, screening for conditions 
against the JCSG Core Suite (Qiagen). At a protein concen­
tration of 10 mg rnL-1 and 1: 1 well-to-protein ratio, several 
screen conditions gave spindle-shaped or fusiform crystals. 
The most ordered crystals grew against wells containing 0.1 
M phosphate-citrate (pH 4.2), 1.6 M sodium dihydrogen 
phosphate, and 0.4 M dipotassium hydrogen phosphate 
(JCSG IV #94). The largest crystals were -0.2 mm in the 
longest dimension. 
Crystals "'.ere n_iounted in Mylar loops (LithoLoops, 
�olecular D1men�10ns) and flash frozen ( 46) in liquid 
mtrogen after passmg for a few seconds through a solution 
containing the well solutes plus 20% glycerol. X-ray data and analysis. 
Site-Directed Mutagenesis. 45 
were collected at beamline 22ID (SER-CAT sector) at the 
Advanced Photon Source, Argonne National Laboratory at a 
temperature of 110 K. Data were reduced with the program 
HKL2000 ( 47) and all aspects of structure determination and 
refinement were carried out in the Phenix suite. ( 48) Initial 
Point mutations were generated using the QuikChange
method. (44) Further mutations required to produce a new 
CocE mutant cDNA were generated from the cDNA corre­
sponding to the El 72-173 in the pET-22b ( +) bacterial 
expression vector. All mutants were sequenced in both 50 
directions over the entire coding region. Using plasmid 
DNA as template and primers with specific base-pair altera­
tions, mutations were made by polymerase chain reaction 
with Pfu DNA polymerase for replication fidelity. The PCR 
product was treated with Dpnl endonuclease to digest the 
1 
55 
parenta DNA template. The digested product was trans-
formed into Escherichia coli, amplified, and purified. The 
DNA se_quences of the mutants were confirmed by DNA
sequencmg. 
Protein Expression and Purification. 
The CocE mutants were expressed in Escherichia coli 60 
�L-21 (DE�) cells grown at 37
° C. Protein expression was 
mduced with 1 mM isopropyl-�-thiogalactopyranoside 
(Sigma-Aldri�h) for about 15 h at 18
° C. Cells were pelleted, 
resuspended m 50 mM Tris-HCI, pH 8.0, 150 mM NaCl 
bu_ffer with protease inhibitor cocktail (Sigma) and lysed 65 
usmg a French press (Thermo Fisher Scientific). The 6His­
tagged enzymes were then enriched using HisPur cobalt 
phasing was done by molecular replacement (Phaser (49) 
module) using the structure of unliganded cocaine esterase 
25 (PDB code 3121). Subsequent model refinement and 
ad�ition of ordered solvent was carried out using the auto­
bmld and refinement modules of Phenix with manual 
rebuilding in Coot, (50) which was also used to introduce the 
sequence changes into the model (Tl 72R, G 173Q L196C, 
and 1301 C). Data reduction and model parameters are given 
in Table 4. 
PEGylation.
Purified enzyme was conjugated with maleimide-linked 
branched poly(ethylene glycol) (PEG) with molecular 
weight of 40 kDa (JenKem Technology, Allen, Tex.) over­
night in PBS buffer, pH 7.4 at the PEG to enzyme molar ratio 
of 20. The PEGylated protein was purified by using the same 
HisPur cobalt resin mentioned above. 
In Vivo Studies. 
Male CD-1 mice (25-30 g) were purchased from Harlan
(Indianapolis, Ind.) and were housed in groups of four mice 
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per cage. All mice were allowed ad libitum access to food 
and water and were maintained on a 12 h light-dark cycle 
with lights on at 6:30 a.m. in a room kept at a temperature 
of 21-22° C. Experiments were performed in accordance
with the Guide for the Care and Use of Laboratory Animals 
as adopted and promulgated by the National Institutes of 
Health. The experimental protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) at 
the University of Kentucky. 
The purified enzyme was administrated intravenously 
(i.v., via tail vein) and (-)-cocaine HCl ( obtained from 
National Institute on Drug Abuse, Bethesda, Md.) was 
administered intraperitoneally, at a volume of about 0.2 
mL/mouse. Cocaine-induced toxicity was characterized by 
the occurrence of lethality. Lethality was defined as cessa­
tion of observed movement and respiration. A single dose 
(30 mg/kg) of E196-301 with or without the PEGylation was 
administered intravenously (i.v.) 1 min before the first 
intraperitoneal (i.p.) administration of 180 mg/kg cocaine 
(n= 5). Then, the mice were challenged again daily with 180 
mg/kg cocaine (i.p.) until no mouse survived. Following 
cocaine administration, mice were immediately placed indi­
vidually for observation. The presence or absence of lethal­
ity was recorded for 60 min following cocaine administra­
tion. 
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INCORPORATION BY REFERENCE 
All publications, patents, and patent applications men­
tioned in this specification are herein incorporated by ref­
erence to the same extent as if each individual publication, 
patent, or patent application was specifically and individu­
ally indicated to be incorporated by reference. 
It will be understood that various details of the present 
disclosure can be changed without departing from the scope 
10 of the subject matter disclosed herein. Furthermore, the 
foregoing description is for the purpose of illustration only, 
and not for the purpose of limitation. 
Throughout this document, various references are men-
15 tioned. All such references are incorporated herein by ref­
erence, including the references set forth in the following 
list: 
(1) UNODC. (2010) World Drug Report 2010, United
Nations Publication, Sales No. E.10.XI.13.
20 (2) Karila, L., Gorelick, D., Weinstein, A., Noble, F., 
Benyamina, A., Coscas, S., Blecha, L., Lowenstein, W., 
Martinat, J. L., Reynaud, M., and Lepine, J. P. (2008) 
New treatments for cocaine dependence: A focused 
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90 
ATGGTGGACGGGAATTACAGTGTTGCCTCGAACGTGATGGTTCCGATGCGTGATGGGGTGCGTCTGGCGGTCGACCTGTACCGACCAGAT 
91 
180 
GCTGATGGACCTGTTCCGGTCCTGCTGGTTCGCAACCCATACGACAAGTTCGACGTGTTCGCGTGGTCGACGCAGTCGACAAACTGGCTT 
181 
270 
GAGTTCGTGCGTGATGGCTATGCCGTGGTCATTCAAGACACGCGTGGCTTGTTCGCATCGGAAGGTGAGTTCGTCCCGCACGTTGACGAC 
271 
360 
GAAGCTGACGCCGAGGATACGTTGAGCTGGATTCTGGAACAAGCGTGGTGCGACGGCAATGTGGGCATGTTCGGCGTTTCGTACTTGGGT 
360 
450 
GTGACCCAGTGGCAGGCCGCCGTATCCGGCGTTGGTGGGCTGAAGGCGATCGCGCCGTCCATGGCGTCGGCGGACTTGTACCGCGCCCCG 
450 
540 
TGGTACGGCCCTGGTGGTGCGCTTTCAGTCGAGGCGCTGTTGGGCTGGTCAGCTCTCATAGGTACTGGGCTCATCACGTCGAGGTCTGAC 
541 
630 
GCCCGGCCCGAAGACGCAGCCGACTTCGTCCAACTCGCAGCAATTCTCAATGACGTCGCTGGCGCGGCGTCGGTCACGCCCCTGGCCGAG 
631 
720 
CAACCGCTTCTGGGCCGACTGATTCCGTGGGTGATCGATCAGGTTGTCGATCACCCCGACAACGATGAATCATGGCAGTCCATTAGCTTG 
721 
810 
TTTGAACGACTCGGCGGGTTGGCAACACCGGCCTTGATCACGGCTGGGTGGTACGACGGGTTCGTCGGCGAATCGTTGCGCACTTTCGTT 
811 
900 
GCGGTCAAGGACAATGCCGACGCACGTTTGGTTGTCGGCCCTTGGAGTCACAGCAACCTCACTGGTCGGAATGCGGACCGGAAGTTCGGC 
901 
990 
ATTGCCGCGACCTACCCGATTCAAGAAGCCACCACGATGCACAAGGCATTCTTCGACCGGCACCTCCGCGGCGAGACCGATGCACTCGCA 
991 
1080 
GGCGTCCCCAAAGTGCGGCTGTTCGTAATGGGCATCGATGAGTGGCGTGACGAAACGGACTGGCCACTGCCGGACACGGCGTATACGCCC 
1081 
1170 
TTCTATCTTGGAGGTAGCGGGGCTGCGAATACCTCCACGGGTGGTGGAACACTGTCGACGTCGATTTCCGGAACTGAATCTGCTGACACC 
1171 
1260 
TACCTGTATGATCCGGCCGATCCCGTGCCTTCGCTCGGGGGGACGCTGCTGTTCCACAACGGAGACAACGGACCCGCCGACCAACGTCCC 
1261 
1350 
ATTCATGACCGGGACGACGTGTTGTGTTACAGCACTGAGGTATTGACCGACCCGGTGGAAGTAACCGGCACCGTCTCCGCCCGGCTGTTC 
1351 
1440 
GTGTCGTCATCAGCGGTGGACACTGATTTCACCGCCAAACTTGTCGACGTATTTCCCGACGGTCGCGCGATCGCGCTGTGTGACGGGATC 
1441 
1530 
GTGCGGATGCGGTACCGCGAGACGTTGGTCAATCCAACCTTGATCGAAGCGGGCGAAATCTACGAGGTTGCTATCGACATGCTTGCAACC 
1531 
1620 
TCGAATGTATTCCTGCCAGGGCATCGCATCATGGTCCAAGTATCAAGTAGCAACTTCCCGAAATACGACCGCAATTCGAATACCGGCGGA 
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SEQUENCES 
1621 
1710 
GTAATCGCACGGGAACAGCTCGAAGAGATGTGCACCGCCGTGAACCGCATTCACCGAGGACCTGAGCATCCCAGCCACATTGTGCTGCCG 
1711 
ATTATCAAGCGA 
SEQ ID NO, 2 
1 
MVDGNYSVASNVMVPMRDGVRLAVDLYRPDADGPVPVLLVRNPYDKFDVFAWSTQSTNWL 
61 120 
EFVRDGYAVVIQDTRGLFASEGEFVPHVDDEADAEDTLSWILEQAWCDGNVGMFGVSYLG 
121 180 
VTQWQAAVSGVGGLKAIAPSMASADLYRAPWYGPGGALSVEALLGWSALIGTGLITSRSD 
181 240 
ARPEDAADFVQLAAI�NDVAGAASVTPLAEQPLLGRLIPWVIDQVVDHPDNDESWQSISL 
241 300 
FERLGGLATPALITAGWYDGFVGESLRTFVAVKDNADARLVVGPWSHSNLTGRNADRKFG 
301 360 
lAATYPIQEATTMHKAFFDRHLRGETDALAGVPKVRLFVMGIDEWRDETDWPLPDTAYTP 
361 420 
FYLGGSGAANTSTGGGTLSTSISGTESADTYLYDPADPVPSLGGTLLFHNGDNGPADQRP 
421 480 
IHDRDDVLCYSTEVLTDPVEVTGTVSARLFVSSSAVDTDFTAKLVDVFPDGRAIALCDGI 
481 540 
VRMRYRETLVNPTLIEAGEIYEVAIDMLATSNVFLPGHRIMVQVSSSNFPKYDRNSNTGG 
541 
VIAREQLEEMCTAVNRIHRGPEHPSHIVLPIIKR 
Note, Residues labeled in red are, T172, G173, L196, and 1301 
SEQ ID NO, 3 
T172R/G173Q/L196C/I301C CocE 
1 
60 
90 
ATGGTGGACGGGAATTACAGTGTTGCCTCGAACGTGATGGTTCCGATGCGTGATGGGGTGCGTCTGGCGGTCGACCTGTACCGACCAGAT 
91 
180 
GCTGATGGACCTGTTCCGGTCCTGCTGGTTCGCAACCCATACGACAAGTTCGACGTGTTCGCGTGGTCGACGCAGTCGACAAACTGGCTT 
181 
270 
GAGTTCGTGCGTGATGGCTATGCCGTGGTCATTCAAGACACGCGTGGCTTGTTCGCATCGGAAGGTGAGTTCGTCCCGCACGTTGACGAC 
271 
360 
GAAGCTGACGCCGAGGATACGTTGAGCTGGATTCTGGAACAAGCGTGGTGCGACGGCAATGTGGGCATGTTCGGCGTTTCGTACTTGGGT 
360 
450 
GTGACCCAGTGGCAGGCCGCCGTATCCGGCGTTGGTGGGCTGAAGGCGATCGCGCCGTCCATGGCGTCGGCGGACTTGTACCGCGCCCCG 
450 
540 
TGGTACGGCCCTGGTGGTGCGCTTTCAGTCGAGGCGCTGTTGGGCTGGTCAGCTCTCATAGGTCGCCAGCTCATCACGTCGAGGTCTGAC 
541 
630 
GCCCGGCCCGAAGACGCAGCCGACTTCGTCCAACTCGCAGCAATTTGCAATGACGTCGCTGGCGCGGCGTCGGTCACGCCCCTGGCCGAG 
631 
720 
CAACCGCTTCTGGGCCGACTGATTCCGTGGGTGATCGATCAGGTTGTCGATCACCCCGACAACGATGAATCATGGCAGTCCATTAGCTTG 
721 
810 
TTTGAACGACTCGGCGGGTTGGCAACACCGGCCTTGATCACGGCTGGGTGGTACGACGGGTTCGTCGGCGAATCGTTGCGCACTTTCGTT 
811 
900 
GCGGTCAAGGACAATGCCGACGCACGTTTGGTTGTCGGCCCTTGGAGTCACAGCAACCTCACTGGTCGGAATGCGGACCGGAAGTTCGGC 
901 
990 
TGCGCCGCGACCTACCCGATTCAAGAAGCCACCACGATGCACAAGGCATTCTTCGACCGGCACCTCCGCGGCGAGACCGATGCACTCGCA 
991 
1080 
GGCGTCCCCAAAGTGCGGCTGTTCGTAATGGGCATCGATGAGTGGCGTGACGAAACGGACTGGCCACTGCCGGACACGGCGTATACGCCC 
1081 
1170 
TTCTATCTTGGAGGTAGCGGGGCTGCGAATACCTCCACGGGTGGTGGAACACTGTCGACGTCGATTTCCGGAACTGAATCTGCTGACACC 
1171 
1260 
TACCTGTATGATCCGGCCGATCCCGTGCCTTCGCTCGGGGGGACGCTGCTGTTCCACAACGGAGACAACGGACCCGCCGACCAACGTCCC 
1261 
1350 
ATTCATGACCGGGACGACGTGTTGTGTTACAGCACTGAGGTATTGACCGACCCGGTGGAAGTAACCGGCACCGTCTCCGCCCGGCTGTTC 
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SEQUENCES 
1351 
1440 
GTGTCGTCATCAGCGGTGGACACTGATTTCACCGCCAAACTTGTCGACGTATTTCCCGACGGTCGCGCGATCGCGCTGTGTGACGGGATC 
1441 
1530 
GTGCGGATGCGGTACCGCGAGACGTTGGTCAATCCAACCTTGATCGAAGCGGGCGAAATCTACGAGGTTGCTATCGACATGCTTGCAACC 
1531 
1620 
TCGAATGTATTCCTGCCAGGGCATCGCATCATGGTCCAAGTATCAAGTAGCAACTTCCCGAAATACGACCGCAATTCGAATACCGGCGGA 
1621 
1710 
GTAATCGCACGGGAACAGCTCGAAGAGATGTGCACCGCCGTGAACCGCATTCACCGAGGACCTGAGCATCCCAGCCACATTGTGCTGCCG 
1711 
ATTATCAAGCGA 
SEQ ID NO, 4 
T172R/G173Q/L196C/1301C CocE 
1 
MVDGNYSVASNVMVPMRDGVRLAVDLYRPDADGPVPVLLVRNPYDKFDVFAWSTQSTNWL 
61 120 
EFVRDGYAVVIQDTRGLFASEGEFVPHVDDEADAEDTLSWILEQAWCDGNVGMFGVSYLG 
121 180 
VTQWQAAVSGVGGLKAIAPSMASADLYRAPWYGPGGALSVEALLGWSALIGgQLITSRSD 
181 240 
ARPEDAADFVQLAAifNDVAGAASVTPLAEQPLLGRLIPWVIDQVVDHPDNDESWQSISL 
241 300 
FERLGGLATPALITAGWYDGFVGESLRTFVAVKDNADARLVVGPWSHSNLTGRNADRKFG 
301 360 
fAATYPIQEATTMHKAFFDRHLRGETDALAGVPKVRLFVMGIDEWRDETDWPLPDTAYTP 
361 420 
FYLGGSGAANTSTGGGTLSTSISGTESADTYLYDPADPVPSLGGTLLFHNGDNGPADQRP 
421 480 
IHDRDDVLCYSTEVLTDPVEVTGTVSARLFVSSSAVDTDFTAKLVDVFPDGRAIALCDGI 
481 540 
VRMRYRETLVNPTLIEAGEIYEVAIDMLATSNVFLPGHRIMVQVSSSNFPKYDRNSNTGG 
541 
VIAREQLEEMCTAVNRIHRGPEHPSHIVLPIIKR 
Note, Residues labeled in red are, R172, Q173, C196, and C301 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 4 
<210> SEQ ID NO 1 
<211> LENGTH, 1722 
<212> TYPE, DNA 
<213> ORGANISM, Rhodococcus sp. MBl 
<400> SEQUENCE, 1 
atggtggacg ggaattacag tgttgcctcg aacgtgatgg ttccgatgcg tgatggggtg 
cgtctggcgg tcgacctgta ccgaccagat gctgatggac ctgttccggt cctgctggtt 
cgcaacccat acgacaagtt cgacgtgttc gcgtggtcga cgcagtcgac aaactggctt 
gagttcgtgc gtgatggcta tgccgtggtc attcaagaca cgcgtggctt gttcgcatcg 
gaaggtgagt tcgtcccgca cgttgacgac gaagctgacg ccgaggatac gttgagctgg 
attctggaac aagcgtggtg cgacggcaat gtgggcatgt tcggcgtttc gtacttgggt 
gtgacccagt ggcaggccgc cgtatccggc gttggtgggc tgaaggcgat cgcgccgtcc 
atggcgtcgg cggacttgta ccgcgccccg tggtacggcc ctggtggtgc gctttcagtc 
gaggcgctgt tgggctggtc agctctcata ggtactgggc tcatcacgtc gaggtctgac 
gcccggcccg aagacgcagc cgacttcgtc caactcgcag caattctcaa tgacgtcgct 
ggcgcggcgt cggtcacgcc cctggccgag caaccgcttc tgggccgact gattccgtgg 
gtgatcgatc aggttgtcga tcaccccgac aacgatgaat catggcagtc cattagcttg 
60 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
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31 
-continued
tttgaacgac tcggcgggtt 
ttcgtcggcg aatcgttgcg 
gttgtcggcc cttggagtca 
attgccgcga cctacccgat 
cacctccgcg gcgagaccga 
ggcatcgatg agtggcgtga 
ttctatcttg gaggtagcgg 
tcgatttccg gaactgaatc 
tcgctcgggg ggacgctgct 
attcatgacc gggacgacgt 
gtaaccggca ccgtctccgc 
accgccaaac ttgtcgacgt 
gtgcggatgc ggtaccgcga 
tacgaggttg ctatcgacat 
atggtccaag tatcaagtag 
gtaatcgcac gggaacagct 
cctgagcatc ccagccacat 
<210> SEQ ID NO 2 
<211> LENGTH, 574 
<212> TYPE, PRT 
ggcaacaccg gccttgatca 
cactttcgtt gcggtcaagg 
cagcaacctc actggtcgga 
tcaagaagcc accacgatgc 
tgcactcgca ggcgtcccca 
cgaaacggac tggccactgc 
ggctgcgaat acctccacgg 
tgctgacacc tacctgtatg 
gttccacaac ggagacaacg 
gttgtgttac agcactgagg 
ccggctgttc gtgtcgtcat 
atttcccgac ggtcgcgcga 
gacgttggtc aatccaacct 
gcttgcaacc tcgaatgtat 
caacttcccg aaatacgacc 
cgaagagatg tgcaccgccg 
tgtgctgccg attatcaagc 
<213> ORGANISM, Rhodococcus sp. MBl 
<400> SEQUENCE, 2 
cggctgggtg gtacgacggg 
acaatgccga cgcacgtttg 
atgcggaccg gaagttcggc 
acaaggcatt cttcgaccgg 
aagtgcggct gttcgtaatg 
cggacacggc gtatacgccc 
gtggtggaac actgtcgacg 
atccggccga tcccgtgcct 
gacccgccga ccaacgtccc 
tattgaccga cccggtggaa 
cagcggtgga cactgatttc 
tcgcgctgtg tgacgggatc 
tgatcgaagc gggcgaaatc 
tcctgccagg gcatcgcatc 
gcaattcgaa taccggcgga 
tgaaccgcat tcaccgagga 
ga 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala 
20 25 30 
Asp 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
32 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1722 
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33 
-continued
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
Ala Gly Glu Ile 
500 
485 490 495 
Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser 
505 510 
Asn 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 
<210> SEQ ID NO 3 
<211> LENGTH, 1722 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized 
570 
34 
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-continued
<400> SEQUENCE, 3 
atggtggacg ggaattacag tgttgcctcg aacgtgatgg ttccgatgcg tgatggggtg 
cgtctggcgg tcgacctgta ccgaccagat gctgatggac ctgttccggt cctgctggtt 
cgcaacccat acgacaagtt cgacgtgttc gcgtggtcga cgcagtcgac aaactggctt 
gagttcgtgc gtgatggcta tgccgtggtc attcaagaca cgcgtggctt gttcgcatcg 
gaaggtgagt tcgtcccgca cgttgacgac gaagctgacg ccgaggatac gttgagctgg 
attctggaac aagcgtggtg cgacggcaat gtgggcatgt tcggcgtttc gtacttgggt 
gtgacccagt ggcaggccgc cgtatccggc gttggtgggc tgaaggcgat cgcgccgtcc 
atggcgtcgg cggacttgta ccgcgccccg tggtacggcc ctggtggtgc gctttcagtc 
gaggcgctgt tgggctggtc agctctcata ggtcgccagc tcatcacgtc gaggtctgac 
gcccggcccg aagacgcagc cgacttcgtc caactcgcag caatttgcaa tgacgtcgct 
ggcgcggcgt cggtcacgcc cctggccgag caaccgcttc tgggccgact gattccgtgg 
gtgatcgatc aggttgtcga tcaccccgac aacgatgaat catggcagtc cattagcttg 
tttgaacgac tcggcgggtt ggcaacaccg gccttgatca cggctgggtg gtacgacggg 
ttcgtcggcg aatcgttgcg cactttcgtt gcggtcaagg acaatgccga cgcacgtttg 
gttgtcggcc cttggagtca cagcaacctc actggtcgga atgcggaccg gaagttcggc 
tgcgccgcga cctacccgat tcaagaagcc accacgatgc acaaggcatt cttcgaccgg 
cacctccgcg gcgagaccga tgcactcgca ggcgtcccca aagtgcggct gttcgtaatg 
ggcatcgatg agtggcgtga cgaaacggac tggccactgc cggacacggc gtatacgccc 
ttctatcttg gaggtagcgg ggctgcgaat acctccacgg gtggtggaac actgtcgacg 
tcgatttccg gaactgaatc tgctgacacc tacctgtatg atccggccga tcccgtgcct 
tcgctcgggg ggacgctgct gttccacaac ggagacaacg gacccgccga ccaacgtccc 
attcatgacc gggacgacgt gttgtgttac agcactgagg tattgaccga cccggtggaa 
gtaaccggca ccgtctccgc ccggctgttc gtgtcgtcat cagcggtgga cactgatttc 
accgccaaac ttgtcgacgt atttcccgac ggtcgcgcga tcgcgctgtg tgacgggatc 
gtgcggatgc ggtaccgcga gacgttggtc aatccaacct tgatcgaagc gggcgaaatc 
tacgaggttg ctatcgacat gcttgcaacc tcgaatgtat tcctgccagg gcatcgcatc 
atggtccaag tatcaagtag caacttcccg aaatacgacc gcaattcgaa taccggcgga 
gtaatcgcac gggaacagct cgaagagatg tgcaccgccg tgaaccgcat tcaccgagga 
cctgagcatc ccagccacat tgtgctgccg attatcaagc ga 
<210> SEQ ID NO 4 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthesized 
<400> SEQUENCE, 4 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
36 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1722 
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-continued
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
Asp 
145 
Glu 
130 135 140 
Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly 
150 155 
Ala Leu Ser 
Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Arg Gln Leu Ile 
165 170 175 
Val 
160 
Thr 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Cys Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
Ala 
Val 
225 
Phe 
Glu 
210 
Val 
195 200 205 
Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val 
215 220 
Ile Asp Gln 
Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
230 235 240 
Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
Asn 
Tyr 
305 
His 
275 280 285 
Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Cys Ala Ala Thr 
290 295 300 
Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
310 315 320 
Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
38 
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-continued
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
We claim: 
1. A cDNA molecule comprising the sequence of SEQ ID
NO: 3. 
2. A cDNA molecule comprising a nucleic acid sequence
which encodes a cocaine esterase (CocE) polypeptide vari­
ant, comprising the amino acid sequence of SEQ ID NO: 4. 
_3: A cocain� esterase (CocE) polypeptide variant, com­
pnsmg t_he am11;10 acid sequence of SEQ ID NO: 2, including 
the ammo acid sequences mutations: T172R, G173Q 
L196C, and 1301 C. 
_4: A cocaine esterase (CocE) polypeptide variant, com­
pnsmg the amino acid sequence of SEQ ID NO: 4, or the 
amino acid sequence encoded by the nucleic acid sequence 
of SEQ ID NO: 3. 
5. The CocE polypeptide variant of claim 4, comprising at
least one cross-subunit disulfide bond. 
6. The CocE polypeptide variant of claim 4, wherein the
at least one cross-subunit disulfide bond is a bond between 
C196a and C301b, or C301a and C196b. 
7. The CocE polypeptide variant of claim 4, having a
half-life of greater than about 100 days at 37° C. 
8. The CocE polypeptide variant of claim 4, further
comprising at least one polyethylene glycol polymer chain 
attached thereto. 
20 
9. The CocE polypeptide variant of claim 5, wherein the
enzyme is conjugated to the polyethylene glycol polymer 
and the polyethylene glycol polymer maleimide-linked 
25 
branched poly(ethylene glycol) (PEG).
10. A pharmaceutical composition comprising the CocE
polypeptide variant of claim 4; and a suitable pharmaceuti­
cally carrier. 
11. The pharmaceutical composition comprising of claim
30 
10, and further comprising at least one polyethylene glycol
polymer chain attached thereto. 
12. A method of treating a cocaine-induced condition
comprising administering to an individual an effective 
amount of the CocE polypeptide variant of claim 4 to 
35 
accelerate cocaine metabolism and produce biologically 
inactive metabolites. 
. 13. T�e meth?� of claim 12, wherein said CocE polypep­
tide vanant exhibits a one-hundred-fold or more increase in 
cocaine hydrolysis catalytic efficiency as compared to a 
40 
mutant that includes only the Tl 72R/G 173Q mutations. 
14. The method of claim 12, wherein said CocE polypep­
tide variant provides protection from a lethal dose of cocaine 
for at least 72 hours. 
* * * * *
